The Cancer Drug Development Forum (CDDF) in collaboration with the Society for Immunotherapy of Cancer (SITC) have the great pleasure to invite you to take part in the 6th Immunotherapy of Cancer Conference (ITOC6) – the leading European conference providing a global platform for translational research in the field of immuno-oncology.

The ITOC series of conferences is the premier meeting in Europe for scientific exchange, networking and education within the cancer immunotherapy field.

The programme will focus on the latest challenges of translational research with a special emphasis on innovations in combination therapy, immuno-monitoring and biomarker development.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>WELCOME LETTER</td>
<td>4</td>
</tr>
<tr>
<td>CANCER DRUG DEVELOPMENT FORUM &amp; ORGANIZING PARTNERS</td>
<td>5</td>
</tr>
<tr>
<td>ITOCS POSTER PRIZE</td>
<td>5</td>
</tr>
<tr>
<td>CONFERENCE COMMITTEE</td>
<td>6</td>
</tr>
<tr>
<td>ACCREDITATION FOR CONTINUOUS MEDICAL EDUCATION (CME)</td>
<td>6</td>
</tr>
<tr>
<td>PROGRAMME AT A GLANCE</td>
<td>7</td>
</tr>
<tr>
<td>SCIENTIFIC PROGRAMME</td>
<td>8</td>
</tr>
<tr>
<td>POSTER PRESENTATIONS</td>
<td>11</td>
</tr>
<tr>
<td>FLOORPLAN</td>
<td>17</td>
</tr>
<tr>
<td>SPONSORS, EXHIBITORS, PARTNERS</td>
<td>18</td>
</tr>
<tr>
<td>GENERAL INFORMATION</td>
<td>23</td>
</tr>
</tbody>
</table>

This is an ESO recommended event.
WELCOME LETTER

Welcome to the fifth edition of the Immunotherapy of Cancer Conference (ITOC5), the premier meeting for education, scientific exchange and networking within cancer immunotherapy.

This meeting has been growing rapidly into a global platform for translational research in the field of immuno-oncology. The scientific programme with an international faculty will focus on many topics such as Immune Escape, Emerging concepts/novel agents, Oncolytic Viruses, Anti-cancer vaccines, Combination Therapy, Cell therapy, Immuno-monitoring, Microbiome in Immunotherapy.

Organised by the Cancer Drug Development Forum (CDDF), whose mission is to provide a unique platform to facilitate interactions between all stakeholders [academia, regulatory authorities, policymakers, industry, patient advocacy groups and health technology assessors] to improve the efficiency of cancer drug development and in cooperation with the Society for Immunotherapy of Cancer (SITC), the ITOC conference series aim to provide a forum for discussion of early clinical drug development and address its unique challenges.

The conference offers a broad and exciting range of opportunities and tools to gain exposure to experts in various disciplines within Europe and far beyond, and we wish you a very successful and enjoyable ITOC5 in the beautiful city of Berlin.

In addition, we wish to express our sincere gratitude to the entire committee, organising partners and sponsors and exhibitors.

Your ideas and suggestions on the future of this conference are welcome. We therefore encourage you to complete the online survey after the conference and please do not hesitate to reach out to our team on site or via email [itoc@medacad.org]

Yours sincerely,

Prof. Dr. Ulrich Keilholz
Conference President

Prof. Dr. Lisa Butterfield
Conference President

Prof. Dr. Volkmar Nüssler
Munich Tumour Center

Prof. Dr. Heinz Zwierzina
Scientific Chairman
CANCER DRUG DEVELOPMENT FORUM

The Cancer Drug Development Forum (CDDF) is a not-for-profit organisation registered in Austria.

It was established in 2001 as Biotherapy Development Association (BDA) and changed name in 2014 to Cancer Drug Development Forum (CDDF).

While BDA’s focus was initially around immunotherapy, in recent years the association has embraced all forms of cancer drug development and therefore wanted a name that better reflects the organisation’s breadth of interests and activities.

CDDF provides a unique forum where all those dedicated to the development of cancer drugs can exchange expertise to find ways to expedite effective oncology drug development and delivery.

For the past 14 years, CDDF has strived to leverage the discussion of the most promising advances in oncology drug development, uniting experts from academia, pharmaceutical industry and regulatory authorities in the quest of overcoming the main challenges in cancer treatment.

Meeting reports and publications based on previous workshops and events are featured in some of the leading oncology journals. You may access CDDF’s list of publications at: www.cddf.org.

THIS PROGRAM IS PRESENTED IN COLLABORATION WITH

ITOC5 POSTER PRIZE

We are proud to announce the ITOC 5 Poster Prize which will be awarded at the 5th Immunotherapy of Cancer Conference thanks to the generous support of the Tumor Center Munich.

Prizes will be awarded to the three best poster presentations. The winners will receive a certificate and a prize of EUR 1000,-/700,-/500,-.

Winners are selected by the scientific committee according to the following criteria:

- Scientific content/methodology
- Novelty and originality of research
- Ability of the author to present the poster in a concise and clear manner and to answer questions during the dedicated poster sessions.

Poster reviewing-Committee:

- Chairman: Sebastian Kobold (Ludwig-Maximilians-Universität, Germany)
- Leisha Ann Emens (Johns Hopkins Medicine Baltimore, United States)
- Ulrich Keilholz (Charité Comprehensive Cancer Center, Germany)
- Eric Tartour (Hôpital Européen Georges-Pompidou, France)
CONFERENCE COMMITTEE

CONFERENCE PRESIDENTS

- Lisa Butterfield (University of Pittsburgh, United States)
- Ulrich Keilholz (Charité Comprehensive Cancer Center, Germany)

CHAIRMAN OF THE SCIENTIFIC COMMITTEE

- Heinz Zwierzina (Innsbruck University, Austria)

SCIENTIFIC COMMITTEE

- Paolo Ascierto (Istituto Nazionale Tumori, Italy)
- Leisha Ann Emens (Johns Hopkins Medicine Baltimore, United States)
- John Haanen (Netherlands Cancer Institute, The Netherlands)
- Leif Hakansson (Universitetssjukhuset Linköping, Sweden)
- Robert F. Hawkins (The Christie Hospital, United Kingdom)
- Howard L. Kaufman (Replimune Group Inc., United States)
- Samir N. Khleif (Georgia Regents University, United States)
- Sebastian Kobold (Ludwig-Maximilians-Universität, Germany)
- Zihai Li (Medical University of South Carolina, USA)
- Michael May (Bristol-Myers-Squibb, Germany)
- Volkmar Nuessler (Munich Tumour Center, Germany)
- Jose Saro (Roche, Switzerland)
- Barbara Seliger (Martin Luther University Halle-Wittenberg, Germany)
- Wenru Song (Kira Pharmaceuticals, USA)
- Rolf Stahel (University Hospital Zurich, Switzerland)
- Zhen Su (Merck KGaA, Germany)
- Eric Tartour (Hôpital Européen Georges-Pompidou, France)
- Christoph Zielinski (Medical University of Vienna, Austria)

ACCREDITATION FOR CONTINUOUS MEDICAL EDUCATION (CME)

The 5th ImmunoTherapy of Cancer Conference, Prague, Czech Republic (March 19 – 21, 2018) has been granted 15 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

European Accreditation is granted by the EACCME in order to allow participants who attend the above mentioned activity to validate their credits in their own country.
# Programme at a Glance

## Monday, March 19, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>Registration Opens</td>
</tr>
<tr>
<td>11.00 – 11.10</td>
<td>Welcome Address</td>
</tr>
<tr>
<td>11.10 – 11.40</td>
<td>Opening Lecture</td>
</tr>
<tr>
<td>11.40 – 13.10</td>
<td>Opening Plenary Symposium 1: Overcoming Immune Escape</td>
</tr>
<tr>
<td>13.10 – 14.00</td>
<td>Lunch</td>
</tr>
<tr>
<td>14.00 – 15.50</td>
<td>Plenary Symposium 2: Emerging concepts / novel agents (1)</td>
</tr>
<tr>
<td></td>
<td><strong>NEW:</strong> Hot Topic Interactive Experts’ Session: Impact of the Microbiome in Immunotherapy</td>
</tr>
<tr>
<td>15.50 – 16.20</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>16.20 – 18.20</td>
<td>Plenary Symposium 2: Emerging concepts / novel agents (2)</td>
</tr>
<tr>
<td>18.20</td>
<td>Welcome Reception and Poster Viewing</td>
</tr>
</tbody>
</table>

## Tuesday, March 20, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 – 10.30</td>
<td>Plenary Symposium 3: Oncolytic Viruses &amp; Innate Immunity</td>
</tr>
<tr>
<td></td>
<td><strong>NEW:</strong> Hot Topic Interactive Experts’ Session: Oncolytic Viruses</td>
</tr>
<tr>
<td>10.30 – 11.00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11.00 – 12.35</td>
<td>Plenary Symposium 4: Anti-cancer vaccines</td>
</tr>
<tr>
<td>12.35 – 14.00</td>
<td>Lunch</td>
</tr>
<tr>
<td>14.00 – 15.00</td>
<td><strong>NEW:</strong> Hot Topic Interactive Experts’ Session: Combinations to target immune excluded and immune desert solid Tumours</td>
</tr>
<tr>
<td>15.00-15.45</td>
<td>Lifetime Award – Carl June</td>
</tr>
<tr>
<td>15.45 – 16.15</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>16.15 – 17.25</td>
<td>Plenary Symposium 5: Cell therapy</td>
</tr>
<tr>
<td>17.25 – 18.25</td>
<td>Plenary Session 6 – Young Researcher Session</td>
</tr>
<tr>
<td>18.25 – 19.30</td>
<td>Poster Viewing with Presenters</td>
</tr>
<tr>
<td>20.00 – 23.00</td>
<td>ITOC5 Conference Dinner</td>
</tr>
</tbody>
</table>

## Wednesday, March 21, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 – 10.30</td>
<td>Plenary Symposium 7: Monitoring of Immune response</td>
</tr>
<tr>
<td>10.30 – 11.00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11.00 – 12.00</td>
<td>Plenary Symposium 8: Clinical Breakthrough with Immunotherapy</td>
</tr>
<tr>
<td></td>
<td><strong>Joint Session with ESMO</strong></td>
</tr>
<tr>
<td>12.00 – 12.30</td>
<td>Best Poster Awards &amp; Closing Remarks</td>
</tr>
<tr>
<td>12.30 – 13.30</td>
<td>Lunch</td>
</tr>
</tbody>
</table>

---

**Monday, March 19, 2018**

- **09.00** Registration Opens
- **11.00 – 11.10** Welcome Address
- **11.10 – 11.40** Opening Lecture
- **11.40 – 13.10** Opening Plenary Symposium 1: Overcoming Immune Escape
- **13.10 – 14.00** Lunch
- **14.00 – 15.50** Plenary Symposium 2: Emerging concepts / novel agents (1)
  - **NEW:** Hot Topic Interactive Experts’ Session: Impact of the Microbiome in Immunotherapy
- **15.50 – 16.20** Coffee Break
- **16.20 – 18.20** Plenary Symposium 2: Emerging concepts / novel agents (2)
- **18.20** Welcome Reception and Poster Viewing

**Tuesday, March 20, 2018**

- **08.30 – 10.30** Plenary Symposium 3: Oncolytic Viruses & Innate Immunity
  - **NEW:** Hot Topic Interactive Experts’ Session: Oncolytic Viruses
- **10.30 – 11.00** Coffee Break
- **11.00 – 12.35** Plenary Symposium 4: Anti-cancer vaccines
- **12.35 – 14.00** Lunch
- **14.00 – 15.00** **NEW:** Hot Topic Interactive Experts’ Session: Combinations to target immune excluded and immune desert solid Tumours
- **15.00-15.45** Lifetime Award – Carl June
- **15.45 – 16.15** Coffee Break
- **16.15 – 17.25** Plenary Symposium 5: Cell therapy
- **17.25 – 18.25** Plenary Session 6 – Young Researcher Session
- **18.25 – 19.30** Poster Viewing with Presenters
- **20.00 – 23.00** ITOC5 Conference Dinner

---

**Wednesday, March 21, 2018**

- **08.30 – 10.30** Plenary Symposium 7: Monitoring of Immune response
- **10.30 – 11.00** Coffee Break
- **11.00 – 12.00** Plenary Symposium 8: Clinical Breakthrough with Immunotherapy
  - **Joint Session with ESMO**
- **12.00 – 12.30** Best Poster Awards & Closing Remarks
- **12.30 – 13.30** Lunch
MONDAY, MARCH 19, 2018

09.00
Registration Opens

11.00 – 11.10
Welcome Address
Heinz Zwierzina, Innsbruck, Austria

11.10 – 11.40
Impact of translational research on current immunotherapy trial programs
Ulrich Keilholz, Berlin, Germany

11.40 – 13.10
Opening
Plenary Symposium 1: Overcoming Immune Escape
Chair: Lisa Butterfield, Ulrich Keilholz

11.40 – 12.10
Tumor/Immune cell metabolism
Ping-Chih Ho, Lausanne, Switzerland

12.10 – 12.40
Current understanding of resistance to immunotherapy
Samir Khleif, Augusta, GA, USA

12.40 – 13.10
Novel genomics tools for cancer immunotherapy
Jacques Banchereau, Bar Harbor, ME, USA

13.10 – 14.00
Lunch

14.00 – 15.50
Plenary Symposium 2: Emerging concepts / novel agents (1)
Chair: Samir Khleif, John Haanen

14.00 – 15.00
NEW: Hot Topic Interactive Experts’ Session: Impact of the Microbiome in Immunotherapy
The impact of the microbiome on anti-tumor immunity and immunotherapy
Andreas Diefenbach, Berlin, Germany

14.00 – 15.00
The role of the Microbiome for cancer therapy
TBC

15.00 – 15.25
STING activation sequenced with immune checkpoint modulators overcomes immune tolerance
Leisha Emens, Baltimore, MD, USA

15.25 – 15.50
IDO inhibition in combination with checkpoint inhibition
Jason Luke, Chicago, IL, USA

16.20 – 18.20
Plenary Symposium 2: Emerging concepts / novel agents (2)
Chair: Paolo Ascierto, Sebastian Kobold

16.20 – 16.45
Combination of anti-LAG 3 antibodies with other checkpoint inhibitors
Paolo Ascierto, Naples, Italy

16.45 – 17.10
TLR and checkpoint inhibitor mediated immune modulation in tumor draining lymph nodes
Tanja de Gruijl, Amsterdam, Netherlands

17.10 – 17.35
Platelets, GARP and Cancer Immunotherapy
Zihai Li, Charleston, SC, USA

17.35 – 17.50
Immune landscape analysis to identify targets for immunotherapy across human carcinomas
\[A1\]
J. Schnappinger\(^1\), T. Straub\(^1\), S. Lee\(^2\), T. Schiergens\(^2\),
R. Oberneder\(^3\), E. Nößner\(^4\);
\(^1\)Immunoanalytics, Helmholtz Center, Munich, Germany,
\(^2\)Biomedical Center, Molecular Biology, Munich, Germany,
\(^3\)Biobank under the administration of the Human Tissue and Cell Research Foundation, Department of General, Visceral and Transplantation Surgery, Hospital of the LMU, Munich, Germany,
\(^4\)Urological Clinic Munich-Planegg, Munich, Germany.

17.50 – 18.05
Circulating regulatory T-cells and the clinical outcome of VEGF-targeted treatment of metastatic colorectal cancer patients: focused on KRAS status and primary tumour sidedness
\[A2\]
L. Zdrazilova-Dubska\(^1\), E. Budinska\(^1\), B. Bencsikova\(^1\),
K. Pilatova\(^2\), R. Obermannova\(^1\), R. Nenutil\(^1\), D. Valík\(^1\);
\(^1\)Masaryk Memorial Cancer Institute, Brno, Czech Republic,
\(^2\)Masaryk University, Brno, Czech Republic.

18.05 – 18.20
The use of EGFR-CD3 bispecific antibody and antigen-specific high avidity T cells to target cancer associated fibroblasts and cancer cells within a melanoma organoid system
\[A3\]
N. Reddy\(^1\), B. Chung\(^2\), E. Chu\(^3\), A. Esmaeili\(^1\), T. Tu\(^1\), P. Lee; City of Hope National Cancer Center, Duarte, CA, United States.

18.20
Welcome Reception and Poster Viewing
TUESDAY, MARCH 20, 2018

08.30 – 10.30
Plenary Symposium 3: Oncolytic Viruses & Innate Immunity
Chair: Leif Hakansson, Eric Tartour

08.30 – 09.30
NEW: Hot Topic Interactive Experts’ Session: Oncolytic Viruses
Michael Bergmann, Vienna, Austria

Cancer gene therapy: design of T-SiGn oncolytic viruses to deliver localized combination immunotherapy within the tumor microenvironment
Brian Champion, Oxfordshire, United Kingdom

Engineering Vaccinia Virus for Intratumoral Delivery to Generate “In Situ Vaccination” against Cancer
Liang Deng, New York, NY, United States

09.30 – 09.50
Reprogramming macrophages for tumour immunity
Michele de Palma, Lausanne, Switzerland

09.50 – 10.10
Next generation immunotherapies: NK cells and other targets
Stéphanie Cornen, Marseille, France

10.10 – 10.30
PD-1 expression on innate lymphoid cells
Shoba Amarnath, Newcastle Upon Tyne, United Kingdom

10.30 – 11.00
Coffee Break

11.00 – 12.35
Plenary Symposium 4: Anti-cancer vaccines
Chair: Barbara Seliger, Lei Zheng

11.00 – 11.20
Tumor antigen-specific T cell epitopes - identification and clinical application
Stefan Eichmueller, Heidelberg, Germany

11.20 – 11.40
Mass spectrometry-verified target epitopes for therapeutic cancer vaccine design
Angelika Riemer, Heidelberg, Germany

11.40 – 12.00
Development of DC vaccines and combinations
Lisa Butterfield, Pittsburgh, PA, USA

12.00 – 12.20
Combination therapy with anti-cancer vaccines and checkpoint Inhibitors
Lei Zheng, Baltimore, MD, USA

12.20 – 12.35
The adjuvant effect of melanin is superior to Incomplete Freund adjuvant in a tumor subunit vaccine model

12.35 – 14.00
Lunch

14.00 – 15.00
NEW: Hot Topic Interactive Experts’ Session: Combinations to target immune excluded and immune desert solid Tumours
Please see page 22 for details

15.00-15.45
Presentation of the ITOC Lifetime Award by Heinz Zwierzina

CAR T cells in haematological malignancies: focused on the cure
Carl June, Philadelphia, PA, USA

15.45 – 16.15
Coffee Break

16.15 – 17.25
Plenary Symposium 5: Cell therapy
Chair: Robert Hawkins, Zihai Li

16.15 – 16.35
Adoptive T cell therapy of glioblastoma
Bryan Choi, Boston, MA, USA

16.35 – 17.00
Arming T cells with C-X-C Motive Receptor 6 as a universal approach for tumor directed T cell recruitment
Sebastian Kobold, Munich, Germany

17.00 – 17.25
Personalized Whole Tumour Antigen Vaccines in Ovarian Cancer: Using Tumors for Therapy
Lana Kandalaft, Lausanne, Switzerland

17.25 – 18.25
Plenary Session 6 - Young Researcher Session
Chair: Leisha Emens, Sebastian Kobold

17.25 – 17.40
Omental fat in ovarian cancer induces metabolic and immune alterations
M. Suarez-Carmona1, N. A. Valous2, M. Hampel1, B. M. Lenoir1, S. Schott1, S. Eismann1, I. Zörnig1, D. Jäger1, N. Halama1; 1National Center for Tumor Diseases (NCT), Heidelberg, Germany, 2Applied Tumor Immunity Clinical Cooperation Unit, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany, 3Department of Obstetrics & Gynaecology, Heidelberg University Hospital, Heidelberg, Germany.
17.40 – 17.55
GARP-TGFβ Axis on Activated Platelets Supports Tumor Progression A6
A. Metelli, B. Riesenber, B. Wu, C. Wallace, S. Sun, B. Liu, Z. Li; Medical University of South Carolina, Charleston, SC, United States.

17.55 – 18.10
Preclinical characterization of a PD-1-CD28 fusion receptor in CD4+ T cells for T cell-based immunotherapy of pancreatic cancer and Non-Hodgkin Lymphoma (A7)
F. Rataj, F. Kraus, S. Grassmann, Michael Chaloupek, Justyna Ogonek, Jin Zhang, Svenja Rausch, Stefan Endres and Sebastian Kobold; Ludwig-Maximilian-University, München, Germany.

18.10 – 18.25
Breast cancer immunotherapy using magnetised oncolytic viruses (A8)
H. AL-Janabi1, J. Conner2, Z. Taher1, S. Staniland1, M. Muthana1; 1The Univesity of Sheffield, Sheffield, United Kingdom, 2Virtu biologics, Glasgow, United Kingdom.

18.25 – 19.30
Poster Viewing with Presenters

20.00 – 23.00
ITOC5 Conference Dinner

WEDNESDAY, MARCH 21, 2018

08.30 – 10.30
Plenary Symposium 7: Monitoring of Immune response
Chair: Marco Gerlinger, Luis Paz-Ares

08.30 – 08.50
Detection of tumour-infiltration immune cells by PET
Secondo Lastoria, Naples, Italy

08.50 – 09.10
Tissue biomarkers of response to immunotherapy
Julien Adam, Villejuif, France

09.10 – 09.35
Tumor mutational burden as a predictive biomarker
Solange Peters, Lausanne, Switzerland

09.35 – 09.55
Circulating tumor DNA and response to immunotherapy
Marco Gerlinger, London, United Kingdom

09.55 – 10.10
Determining tumor mutation load using an NGS-based, target gene panel A9
J. C. Machado1, J. Reis1, M. Fernandes1, R. Silva1, L. Cirnes1, R. Chaudhary2, F. Carneiro1, J. L. Costa1; 1IPATIMUP, Porto, Portugal, 2Centro Hospitalar de São João, Porto, Portugal, 3Thermo Fisher Scientific, Carlsbad, CA, United States, 4Faculty of Medicine, Porto, Portugal.
**POSTER PRESENTATIONS**

**POSTER SESSION P01.**

**Preclinical models**

**P01.01** Orthotopic HCC Mouse Models to Predict Response to Immuno Therapy  
C. Hage¹, S. Hoves¹, M. Ashoff¹, L. Strauss¹, M. Perro², F. Herting³, F. Kiessling³, T. Pöschinger³; ¹Roche Innovation Center Munich, Penzberg, Germany, ²Roche Innovation Center Zurich, Zurich, Switzerland, ³RWTH Aachen University, Aachen, Germany.

**P01.02** A new family of potent TLR9 agonists, EnanDIM, which inhibit tumor growth in various syngeneic murine models  
B. Volz¹, K. Kapp¹, D. Oswald¹, B. Wittig², M. Schmidt¹; ¹Mologen AG, Berlin, Germany, ²Foundation Institute Molecular Biology and Bioinformatics, Freie Universitäet Berlin, Berlin, Germany.

**P01.03** Building Kras (G12D)/Trp53 null/Pdx1-cre (KPC) mouse allograft tumor model for efficacy evaluation of combinatory immunotherapie  

**P01.04** Preclinical development of a therapeutic antibody for the treatment of epithelial ovarian carcinoma  
M. Suarez-Carmona¹, D. S. Ferber¹, F. Momburg², M. Meyer³, M. Hampel¹, B. M. Lenoir¹, S. Schott², I. Zörnig¹, D. Jäger¹, N. Halama¹; ¹National Center for Tumor Diseases (NCT), Heidelberg, Germany, ²Applied Tumor Immunity Clinical Cooperation Unit, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany, ³Department of Obstetrics and Gynaecology, Heidelberg University Hospital, Heidelberg, Germany.

**P01.05** A new combination immunotherapy approach with anti-PD-L1 and HER2/neu loaded dendritic cell vaccine along with saponin adjuvant  
C. S. Ozverel¹, I. Karaboz¹, A. Nalbantsoy²; ¹Biology Department, Faculty of Science, Ege University, Izmir, Turkey, ²Bioengineering Department, Faculty of Engineering, Ege University, Izmir, Turkey.

**POSTER SESSION P02.**

**Tumor Immunity and Microenvironment**

**P02.01** Altered type III collagen turnover measured in pre-treatment serum predicts outcome in metastatic melanoma patients treated with Ipilimumab  
C. Jensen¹, D. Madsen³, M. Hansen³, H. Schmidt⁴, I. Svane³, M. Karsdal⁴, N. Willumsen³; ¹Biomarkers & Research, Nordic Bioscience, Herlev, Denmark, ²Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark, ³Center for Cancer Immune Therapy, Department of Haematology and Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark, ⁴Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

**P02.02** Humanized Mouse Models of Triple-Negative and Triple-Positive Breast Cancer for Preclinical Validation of Novel Immunono- Oncology Therapies  
T. E. Kähkönen¹, M. I. Suominen¹, J. M. Halleen¹, T. Haapaniemi¹, A. Tanaka¹, M. Seiler¹, J. Bernoulli¹; ¹Pharmatest Services, Turku, Finland, ²BiositeHisto Ltd, Tampere, Finland, ³Taconic Biosciences, Hudson, NY, United States.
P02.03 Cancer cells regulate Interleukin-22 production to promote tumor growth
C. Voigt1, P. May1, A. Gottschlich1, A. Markota1, D. Wenk1, I. Gerlach1, J. Suárez Gosálvez1, T. Rozicka1, A. Kraechan1, S. Voigt2, G. Stathopoulos3, K. Arendt3, C. Heise1, F. Rataj1, K. Janssen5, M. Königshoff5, H. Winter6, I. Himsl2, W. Thasler1, M. Schnurr1, S. Rothenfußer1, S. Endres1, S. Kobold1; 1Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany, 2Brustzentrum Dritter Orden, Munich, Germany, 3Comprehensive Pneumology Center, Ludwig Maximilian University of Munich, Munich, Germany, 4Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, University of Patras, Rio, Greece, 5Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität, Munich, Germany, 6Department of Thoracic Surgery, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.

P02.04 Omental fat in ovarian cancer induces lymphangiogenesis
D. Ferber1,*, B. Lenoir*, M. Suarez-Carmona1, S. Schott1, I. Zörnig1, D. Jäger1, N. Halama1; 1National Center for Tumor Diseases, Heidelberg, Germany, 2Heidelberg University Hospital, Heidelberg, Germany.

P02.05 Spatial profiling and functional phenotyping of mast cell distribution in human cancer tissues
D. Ferber1, M. Suarez-Carmona1, J. N. Kather1, B. Lenoir1, M. Hampel1, U. Prüfer1, S. Eismann2, S. Schott1, I. Zörnig1, D. Jäger1, N. Halama1; 1Medical Oncology, National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany, 2Heidelberg University Hospital, Heidelberg, Germany.

P02.06 Digital spatial profiling platform allows for spatially-resolved, multiplexed measurement of solid tumor protein distribution and abundance in FFPE tissue sections
A. Winfield; Nanostring, Seattle, WA, United States.

P02.07 In vitro Culture of Tumor Infiltrating Lymphocytes for Adoptive Immunotherapy in Breast Cancer Patients
s. seber1, t. yetisigiti2, b. turgut3, s. Bulus3, S. Ozkan Gürdal3, M. Oznur4, 1Medical Oncology Department, Tekirdag, Turkey, 2Namik Kemal University Hospital, Tekirdag, Turkey, 3Hematology Department, Tekirdag, Turkey, 4Hematology Laboratory, Tekirdag, Turkey, 5Namik Kemal University Hospital, Tekirdag, Turkey, 6General Surgery Department, Tekirdag, Turkey.

P02.08 The role of myeloid-derived suppressor cells in autologous hematopoietic stem cell transplantation
A. Betsch1, O. Rutgeerts1, S. Fevery1, B. Sprangers1, D. Dierickx1, Mark Beckers1; 1KU Leuven, Leuven, Belgium, 2UZ Leuven, Leuven, Belgium.

P02.09 Standard normoxic versus physiological hypoxic culture of AML patients’ whole blood (WB) samples with immunomodulatory Kits yields comparable proportions of Dendritic cells and functional results
F. Doraneh gard1, D. Amberger1, M. Weimann1, C. Boeck1, C. Gunsilius1, C. Kugler1, J. Werner1, D. Kraemer1, A. Rank1, C. Schmid1, H. Schmetzer1; 1University Hospital of LMU, Department for Hematopoietic cell Transplantations, Munich, Germany, 2University Hospital of Tuebingen, Department for Hematology and Oncology, Tuebingen, Germany, 3University Hospital of Oldenburg, Department for Hematology and Oncology, Oldenburg, Germany, 4Municipal Hospital of Augsburg, Department of Hematology and Oncology, Augsburg, Germany.

P02.10 Insights into the tumor microenvironment and human TRBV gene polymorphism revealed by long-amplicon immune repertoire sequencing

P02.11 Tumor-specific neoantigens drive T-cell clonotype convergence
J. C. Machado1, J. Reis1, M. Fernandes2, R. Silva2, L. Cirnes1, F. Carneiro1, J. L. Costa1; 1IPATIMUP, Porto, Portugal, 2Centro Hospitalar de São João, Porto, Portugal, 3Faculty of Medicine, Porto, Portugal.
**P02.12** Soluble immune checkpoints CD27, Lag3, PD-L2 and Tim3 in early stage NSCLC patients  
G. Gamerith\(^1\), H. Hackl\(^1\), P. Wallinger\(^1\), L. Fandel\(^1\), J. Kern\(^2\), F. Augustin\(^1\), E. Lorenz\(^1\), E. Hoflehner\(^1\), F. Mildner\(^1\), P. Moser\(^3\), S. Sprung\(^4\), B. Zelger\(^1\), S. Kreck2, A. Amann\(^1\), G. Schäfer\(^1\), D. Öfner\(^1\), H. Maier\(^1\), Z. Trayanoski\(^1\), H. Zwierzina\(^1\), S. Sopper\(^1\), \(^1\)Medical University of Innsbruck, Department of Internal Medicine V, Innsbruck, Austria, \(^2\)Tyrolean Cancer Research Institute, Innsbruck, Austria, \(^3\)Medical University of Innsbruck, Biocenter, Division of Bioinformatics, Innsbruck, Austria, \(^4\)Medical University of Innsbruck, Department of Visceral, Transplant and Thoracic Surgery, Innsbruck, Austria, \(^5\)LKH Innsbruck, Institute of Pathology, Innsbruck, Austria, \(^6\)Medical University of Innsbruck, Department of Pathology, Innsbruck, Austria.

**P02.13** The influence of stromal cells on CD3+CD8+ tumor infiltrating lymphocyte subpopulations in cancer microtissues  
S. Koeck\(^2\), M. Zwierzina\(^2\), G. Gamerith\(^1\), E. Lorenz\(^1\), J. Kern\(^2\), A. Amann\(^1\), \(^1\)Medical University of Innsbruck, Department of Internal Medicine V, Innsbruck, Austria, \(^2\)Tyrolean Cancer Research Institute, Innsbruck, Austria, \(^3\)Medical University of Innsbruck, Department of Plastic, Reconstructive and Aesthetic Surgery, Innsbruck, Austria.

**POSTER SESSION P03.**  
Primary and Acquired Resistance mechanisms

**P03.01** The role of TopoisomeraseII-α (TOPO II A) as a predictive factor for response to neoadjuvant anthracyclines based chemotherapy in locally advanced breast cancer  
M. M. Gamea; Aswan University, Tanta, Egypt.

**P03.02** miRNA set dysregulation in breast cancer cells can contribute to both primary and acquired resistance to immune checkpoint blockade  
A. Halytyskiy; Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine, Kiev, Ukraine.

**POSTER SESSION P04.**  
Therapeutic modulation of immune checkpoints

**P04.01** Complete clinical remission of stage IV breast cancer with liver, lung, bone and lymph node metastasis combining low-dose checkpoint inhibitors with interleukin-2 (IL-2) and fever range hyperthermia and metronomic low-dose chemotherapy  
R. Kleef; Ralf Kleef Immunology & Integrative Oncology, Vienna, Austria.

**P04.02** Local oncothermia [modulated-electrohyperthermal] against systemic malignancy  

**P04.03** AB680, a potent and selective CD73 small molecule inhibitor, reverses the AMP/adenosine-mediated impairment of immune effector cell activation by immune checkpoint inhibitors  

**P04.04** AB928, a dual antagonist of the A2AR and A2bR adenosine receptors, leads to greater immune activation and reduced tumor growth when combined with chemotherapy  

**P04.05** Immune Modulation of AML-blasts in therapy refractory AML-patient in vivo with clinically approved Response Modifiers improves clinical status, blood cell regeneration and gives rise to leukemiaspecific adaptive and innate immune reactive cells  
C. Schmid\(^1\), M. Atzler\(^2\), A. Rank\(^3\), M. Inngjerdingen\(^4\), A. Rabe\(^5\), D. Deen\(^6\), R. Wang\(^7\), B. Eiz-Vesper\(^8\), H. Schmetzer\(^8\), \(^1\)Dept Med II, Hematopoetic stem cell transplantation, Augsburg University, 86156 Augsburg, Germany, \(^2\)Hematopoetic Cell Transplantation Unit, Dept of Med II, 81377 Munich, Germany, \(^3\)Dept of MedII, Section of Hematopoetic Cell Transplantations, University of Augsburg, 86156 Augsburg, Germany, \(^4\)Dept Immunology, Oslo University Rikshospitalet, 0027 Oslo, Norway, \(^5\)Institute for Transfusion-Medicine, Hannover Medical School, 30625 Hannover, Germany, \(^6\)Hematopoetic Cell Transplantation Unit,Dept of MedI, 81377 Munich, Germany, \(^7\)Dept of MedI, University Hospital of Munich, 81377 Munich, Germany.
POSTER SESSION P05.

Combination therapy

P05.01 Engineering high affinity, soluble T cell receptors for the treatment of cancer

P05.02 4SC-202 increases immunogenicity of tumor cells, induces infiltration of tumor microenvironment with cytotoxic T cells, and primes tumors for cancer immunotherapy

P05.03 Peritumoral gene electrotransfer of interleukin-12 as an adjuvant immunotherapy to intratumoral electrochemotherapy for murine melanoma treatment
K. Ursic, S. Kos, U. Kamensek, M. Cemazar, G. Sersa; 1Institute of Oncology Ljubljana, Department of Experimental Oncology, Ljubljana, Slovenia, 2University of Primorska, Faculty of Health Sciences, Izola, Slovenia, 3University of Ljubljana, Faculty of Health Sciences, Ljubljana, Slovenia.

P05.04 P-MAPA immunotherapy and interleukin-12 on ovarian carcinoma SKOV-3 cells: assessment of the TLR signaling and cytokine/chemokine profile.

P05.05 Impact of natural substances on the efficacy of immunotherapy
M. Luzbetak, N. Süssenguth, B. Mayer; AVT Surgery, Klinikum Großhadern, Munich, Germany.

POSTER SESSION P06.

Anti-cancer vaccines

P06.01 Novel PAP-derived vaccine for the treatment of advanced prostate cancer
P. Le Vu, J. Vadakekolathu, H. Nicholls, D. Christensen, L. Durrant, A. Pockley, S. E. McArde; 1The John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom, 2Statens Institut, Copenhagen, Denmark, 3Cívicla Oncology, Nottingham University, Nottingham, United Kingdom, 4The John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom.

P06.02 HAGE-derived peptide as a vaccine to prevent relapse in TNBC patients: Proof of concepts
D. Nagarajan, L. Durrant, G. Pockley, S. McArde; 1NTU, Nottingham, United Kingdom, 2Scancell Holding plc, Nottingham, United Kingdom.

P06.03 Eliciting protective T cell immunity against EBV-associated malignancies by vaccination
J. Rühl, C. Citterio, C. Leung, C. Münz; 1Institute of Experimental Immunology, Zürich, Switzerland, 2Department of Hematology, University College London Cancer Institute, London, United Kingdom.

POSTER SESSION P07.

Adoptive cell therapy

P07.01 Proof of concept and mode of action of a novel modular platform for adoptive T cell therapy combining bispecific antibodies with synthetic agonistic receptors
C. Karches, M. Benmabre, M. Schmidbauer, M. Kurzay, R. Klaus, M. Geiger, S. Lesch, B. Cadilha, F. Rataj, C. Heise, R. Murr, J. vom Berg, M. Jastroch, D. Lamp, P. Duewell, G. Niederfellner, C. Sustmann, S. Endres, C. Klein, S. Kobold; 1Division of Clinical Pharmacology, München, Germany, 2Roche Innovation Center Zurich, Schlieren, Switzerland, 3Institute of Laboratory Animal Science, Zurich, Switzerland, 4Helmholtz Diabetes Center and German Diabetes Center (DZD), München, Germany, 5Roche Innovation Center Munich, Penzberg, Germany.

P07.02 Mesothelin-targeted bispecific antibodies drive synthetic agonistic receptor - transduced T cells to mediate specific and conditional therapy of human pancreatic cancer models
M. Benmabre, C. Karches, M. Schmidbauer, M. Kurzay, R. Klaus, M. Geiger, F. Rataj, B. Cadilha, J. Keyl, S. Lesch, C. Heise, R. Murr, J. vom Berg, M. Jastroch, D. Lamp, G. Niederfellner, C. Sustmann, S. Endres, C. Klein, S. Kobold; 1Division of Clinical Pharmacology, LMU, Munich, Germany, 2Roche Innovation Centre Zurich, Schlieren, Switzerland, 3Institute of Laboratory Animal Science, University of Zurich, Zurich, Switzerland, 4Helmholtz Diabetes Center and German Diabetes Center (DZD), Helmholtz Zentrum München, Munich, Germany, 5Roche Innovation Centre, Penzberg, Germany.
**POSTER SESSION P07.**

**P07.03** Cytokine-Induced Killer cells combined with anti EGFR monoclonal antibody abrogate triple negative breast cancer metastatization

R. Sommaggio1, E. Cappuzzello1, A. Rosato1,2,  
1Department of Surgery, Oncology and Gastroenterology; Immunology and Oncology Section, University of Padua, Padua, Italy,  
2Department of Clinical and Experimental Oncology, Veneto Institute of Oncology IOV-IRCSS, Padua, Italy.

**P07.04** Depletion of MDSC improves the anti-neuroblastoma effect of adoptive recipient leukocyte infusion in allogeneic bone marrow transplanted mice.

I. Dierckx de Casterlé1, O. Rutgeerts1, S. Fevery1, S. Van Goor1, M. Waer2, A. D. Billiau1, B. Sprangers3;  
1KU Leuven, Leuven, Belgium,  
2Immunologisches Onkologisches Zentrum Köln, Köln, Germany,  
3KU Leuven; University Hospitals Leuven, Leuven, Belgium.

**P07.05** Arming T cells with activating FcγRIIIa receptors for antibody redirected lysis of cancer cells

S. J. Jacobi1, F. Rataj1, F. Asang1, S. Stoiber1, M. Benmebarek2, R. Klaus1, S. Endres1, C. Klein1, S. Kobold1;  
1Center of Integrated Protein Science Munich [CIPS-M] and Division of Clinical Pharmacology, Munich, Germany,  
2Roche Innovation Center Zurich, Schlieren, Switzerland.

---

**POSTER SESSION P08.**

**Monitoring of immunotherapy**

**P08.02** CD73 activity and outcome of advanced melanoma patients treated with nivolumab

S. Morello1, C. Sorrentino1, M. Capone1, D. Giannarelli1, G. Madonna1, D. Mallardo1, A. M. Grimaldi1, A. Pinto1, P. A. Ascierto1,  
1Department of Pharmacy, University of Salerno, Salerno, Italy,  
2Department of Pharmacy, University of Salerno, PhD Program in Drug Discovery and Development, Salerno, Italy,  
3National Cancer Institute “G. Pascale”, Naples, Italy,  
4Regina Elena National Cancer Institute, Rome, Italy.

**P08.04** Positive controls for cytometric in vitro T cell activation test for bladder carcinoma patient stratification and monitoring

P. Hadlova, A. Koladiya, K. Drbal; Charles University, Praha, Czech Republic.

---

**POSTER SESSION P09.**

**Young Researcher Session**

**P09.01** Trends in incidence of head and neck cancers in India

D. Francis; Tagore dental College and Hospital, Chennai, India.

**P09.02** Enhancing Cytokine-Induced Killer [CIK] cell activity with Her2-specific Fc-engineered antibodies and antibody derivatives

E. Cappuzzello1, R. Sommaggio1, C. Keliner1, M. Peipp1, A. Rosato1,2,  
1Department of Surgery, Oncology and Gastroenterology; Immunology and Oncology Section, University of Padua, Padua, Italy,  
2Department of Clinical and Experimental Oncology, Veneto Institute of Oncology IOV-IRCSS, Padua, Italy.

**P09.03** Exploring phenotypic and functional characteristics of cultured tumor infiltrating lymphocytes

M. Rana1, T. Boritch1, A. Draghi1, A. Gokuldass1, M. Donia1,2, I. Svane1,2;  
1Center for Cancer Immune therapy (CCIT), Copenhagen, Denmark,  
2Department of Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.

**P09.04** A novel rMVA combination immunotherapy triggers potent innate and adaptive immune responses against established tumors

Bavarian Nordic GmbH, Planegg, Germany.

**P09.05** Expression of CD73 on MDSCs and CD8+/PD-1+ cells as new possible biomarkers for advanced melanoma patients treated with nivolumab

F. Fratangelo1, S. Morello1, G. Madonna1, M. Capone1, D. Mallardo1, R. Falcone1, A. M. Grimaldi1, E. Simeone1, V. Vanella1, D. Giannarelli1, C. Sorrentino1, A. Pinto1, P. A. Ascierto1;  
1S.C. Oncologia Clinica Sperimentale Melanoma Immunoterapia e Terapie Innovative - IRCCS - Fondazione G. Pascale, Naples, Italy,  
2Dipartimento di Farmacia, Università di Salerno, Fisciano, Italy,  
3Istituto Nazionale Tumori Regina Elena, Rome, Italy.
M1 polarization of tumor-associated macrophages after irradiation of human rectal cancer in patients and 3D co-culture model

V. Stary1, J. Strobl1, A. Beer1, H. Dolznig1, M. Bergmann1; 1Department of Surgery, Medical University of Vienna, Vienna, Austria, 2Division of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna, Vienna, Austria, 3Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria, 4Institute of Genetics, Medical University of Vienna, Vienna, Austria.
FLOORPLAN

STAND NUMBER EXHIBITOR

1 Immudex
2 CleanNA
3 Bio-Technne
4 PerkinElmer
5 MBL International
6 10X Genomics
7 Thermo Fisher Scientific
8 Bristol-Myers Squibb
9 The Cancer Drug Development Forum (CDDF)
10 NanoString Technologies
11 Meso Scale Discovery
12 ProQinase
13 Free Literature
14 NewLink Genetics
15 Agilent
16 The Society for Immunotherapy of Cancer (SITC)
17 Incyte
ACKNOWLEDGMENTS

GRANT DONATORS | SPONSORS | EXHIBITORS | PARTNERS

For questions regarding sponsorship and exhibition, please contact Rose International.

• Contact: Flora van Laer
• E-mail: fvanlaer@rose-international.com
• Telephone: +31 70 383 89 01

We thank all ITOC 5 grant donators, sponsors and partners.
The ITOC5 Organising Committee wishes to gratefully acknowledge our sponsors and exhibitors for supporting the 5th Immunotherapy of Cancer Conference (ITOC5).

GRANT DONATORS

Gilead Sciences Europe Ltd
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

→ View more at www.gilead.com

Merck Sharp & Dohme Corp.
For more than a century, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world.

→ For more information, visit www.msd.com and connect with us on Twitter, LinkedIn and YouTube.

SPONSORS

F. Hoffmann-La Roche Ltd
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

→ View more at www.roche.com

Incyte Corporation
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics.

→ View more at www.incyte.com, and follow @Incyte on Twitter at https://twitter.com/Incyte

NanoString Technologies
NanoString is a life sciences company focused on cancer research and diagnostics. Proven in over 1,000 peer-reviewed publications, the nCounter® System can combine with 3D biology™ technology to create novel biomarkers. The Prosigna® Breast Cancer Prognostic Gene Signature Assay provides FDA 510(k)-cleared diagnostics with the nCounter Dx Analysis System.

→ View more at https://www.nanostring.com/

Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity.

→ For more information, please visit www.thermofisher.com
EXHIBITORS

10x Genomics
10x Genomics’ Chromium™ System supports comprehensive genomics and high-throughput single cell transcriptomics. It enables researchers to discover previously inaccessible genomic information, including phased structural variants, phased single nucleotide variants, Single Cell gene expression and paired full length V(D)J repertoires—while leveraging their existing sequencing systems and workflows.
→ View more at https://www.10xgenomics.com/

Agilent Technologies
Agilent is a leader in life science research tools, providing analytical instruments, software, consumables and services for research laboratories worldwide. Agilent products including Seahorse, iLab, Dako, SureSelect, and mass spec are used in phenotyping, metabolomics, cell metabolism, and mitochondrial toxicity assays; as well as immunotherapy, cancer, and metabolic disease research.
→ View more at https://www.agilent.com/en-us/promotions/seahorse-xf-technology

Bio-Techne
Bio-Techne brings together some of the most referenced brands in life science – R&D Systems, Novus Biologicals, Tocris Bioscience, and ProteinSimple providing innovative, high-quality research tools. Together we are Bio-Techne. Find out how we can be your partner and help you attain your research goals by visiting our stand.

Bristol-Myers Squibb GmbH & Co. KGaA
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines. We are committed to Immuno-Oncology [I-O], a rapidly evolving field that enlists the immune system in the fight against cancer. As we learn more about how cancer evades the immune system, the growing potential of I-O drives our research efforts.
→ View more at https://www.bms.com/

The Cancer Drug Development Forum (CDDF)
The Cancer Drug Development Forum (CDDF) looks forward to welcoming you at the 5th edition of the Immunotherapy of Cancer Conference (ITOC5) in Berlin. We will be available to meet you at the exhibition area, feel free to come and visit us at any time! The (CDDF) is an international organization providing a platform for all stakeholders involved in the development of oncology drugs. The aim of the not-for-profit organization is to accelerate the delivery of effective oncology agents to patients.
→ View more on http://cddf.org

CleanNA
CleanNA’s focuses on supplying an evolving market with high quality products, providing the latest technology, high-efficiency and cost-effective magnetic bead-based kits for both DNA and RNA isolation from various sample sources, for example Whole Blood, FFPE, Plant tissue, etc. A dedicated team combines both scientific and technical knowledge providing an ideal interface between the user and life science application(s).
→ View more at http://www.cleanna.com/

Immudex
Based in Copenhagen, Denmark, Immudex manufactures MHC Dextramers for the detection of antigen-specific T cells in life science research, in vitro diagnostics, and the development of immunotherapeutics and vaccines. Under an agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer Immunotherapy Consortium (CIMT), Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide.
→ View more at www.immudex.com

Incyte Corporation
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics.
→ View more at www.incyte.com, and follow @Incyte on Twitter at https://twitter.com/Incyte
MBL International
MBL International is a life science company focused on providing high quality, innovative, solutions-based products for life science research and clinical diagnostics. MBLI develops and manufactures a broad portfolio of monoclonal and polyclonal antibodies, MHC tetramers, fluorescent and recombinant proteins and ELISA kits for research related to allergy, apoptosis, autophagy, cancer, epigenetics, immunology, and neuroscience.
→ View more at https://www.mblintl.com/

Meso Scale Discovery
Meso Scale Discovery (MSD®) is a leader in high performance, multiplex-enabled biomarker assays for cytokines, toxicology, neurodegeneration and metabolic disease research, used by leading biopharmaceutical and academic researchers in human and animal model studies. MSD’s proprietary electrochemiluminescence (ECL) platform delivers exceptional sensitivity, wide dynamic range and rapid turnaround.
→ View more at: www.mesoscale.com

NanoString Technologies
NanoString is a life sciences company focused on cancer research and diagnostics. Proven in over 1,000 peer-reviewed publications, the nCounter® System can combine with 3D biology™ technology to create novel biomarkers. The Prosigna® Breast Cancer Prognostic Gene Signature Assay provides FDA 510(k)-cleared diagnostics with the nCounter Dx Analysis System.
→ View more at https://www.nanostring.com/

NewLink Genetics
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics’ IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer.
→ View more at: www.newlinkgenetics.com

PerkinElmer
PerkinElmer is a global leader focused on improving human and environmental health, for the better. To accelerate the understanding of human health, we provide our customers with the knowledge, expertise and solutions to better diagnose, treat and prevent disease. Our full Phenoptics™ Research Solution, including Opal™ multiplexed staining reagents, multispectral imaging instrumentation (Vectra® Polaris™, Vectra® and Mantra™ Systems), and inForm® advanced image analysis software, enable immuno-oncology researchers to better understand the complex biology of the tumor microenvironment.
→ View more at www.perkinelmer.com/Phenoptics

ProQinase
ProQinase is a leading CRO for anti-cancer drug discovery providing customized solutions from biochemical and cellular testing to in vivo proof of concept. Apart from single service solutions, ProQinase also carries out integrated drug discovery projects as a ‘one-stop shop’ solution provider. A main focus of ProQinase’s expertise is a versatile immuno-oncology platform including syngeneic mouse models (subcutaneous, orthotopic, metastasis) and supporting immunoassays.
→ View more at www.proqinase.com

The Society for Immunotherapy of Cancer (SITC)
SITC is a 501 [c][3] non-profit professional society of over 1,600 influential scientists and practitioners from around the world who are dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Through emphasis on high-caliber scientific meetings, education, and collaborations, SITC brings together all aspects of cancer immunology and immunotherapy.
→ View more on www.sitcancer.org ; https://twitter.com/sitcancer

Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity.
→ For more information, please visit www.thermofisher.com
THE HOT TOPIC INTERACTIVE EXPERTS’ SESSION ON
“COMBINATIONS TO TARGET IMMUNE EXCLUDED AND IMMUNE DESERT SOLID TUMOURS”
IS SUPPORTED BY A MEDICAL EDUCATION GRANT FROM:

Roche

SYMPOSIUM AGENDA

Tuesday, March 20, 2018 at 14.00 - 15.00hrs
Combinations to target immune excluded and immune desert solid Tumours
Chair: Rudolf Maria Huber

Introduction: NSCLC immune-phenotypes
Rudolf Maria Huber, Munich, Germany

Chemotherapy + checkpoint inhibitors and antiangiogenesis agent: rationale and emerging data
Solange Peters, Lausanne, Switzerland

Checkpoint inhibitor + T cell bispecific: rationale and emerging data
Ignacio Melero, Navarra, Spain

The Hot Topic Interactive Experts’ Session is a new addition to ITOC5 program and aims to encourage an interactive and alternative debate, aiming to educate and engage participants. It will provide delegates attending with a further opportunity to question and exchange with experts in immunotherapy in a concise and interactive format. The session offers a privileged opportunity to interact with, and receive high-level guidance from, experts in the field. The Hot Topic Interactive Experts’ Session is open to all ITOC5 participants.
GENERAL INFORMATION

SECRETARIATS

SECRETARIAT
The Cancer Drug Development Forum (CDDF)
Avenue E. Mounier 83, 1200 Brussels, Belgium
Phone: +32 (0)2 775 02 15
Email: cddf@ecco-org.eu
Website: www.cddf.org

CONFERENCE MATTERS
Vienna Medical Academy
Conference & Society Management
Contact: Catherine Tomek
E-mail: itoc@medacad.org
Telephone: +43 1 405 13 83 18
Website: www.medacad.org

SPONSORSHIP AND EXHIBITION MATTERS
Rose International
Exhibition Management & Congress Consultancy bv
Contact: Flora van Laer
E-mail: fvanlaer@rose-international.com
Telephone: +31 70 383 8901

CONFERENCE VENUE
Mercure Hotel Moa Berlin
Stephanstraße 41
Entrance through Shoppingcenter at Birkenstraße 23, 1st Floor
10559 Berlin, Germany
Telephone: +49 (0) 30 39 40 43 158

HOW TO REACH THE VENUE

• **By car:** Address: Birkenstraße 23
  550 parking spaces in the shopping center “MOA Bogen”
  Direct access to the hotel on the 2nd floor P4 (level 4)

• **By Metro:** Station U9 Birkenstrasse

• **By Bus:** Station 123 Stendaler Strasse
REGISTRATION

Registration Hours
- Monday, March 19, 2018 ______ 09:00 - 18:30 hrs
- Tuesday, March 20, 2018 ______ 07:30 - 18:30 hrs
- Wednesday, March 21, 2018 ___ 08:00 - 13:30 hrs

Registration fees in Euro

<table>
<thead>
<tr>
<th>Payment received:</th>
<th>Early Bird until Dec. 15, 2017</th>
<th>From December 16 to March 9, 2018</th>
<th>On-Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Academia</td>
<td>450,-</td>
<td>550,-</td>
<td>650,-</td>
</tr>
<tr>
<td>Junior Participant1</td>
<td>120,-</td>
<td>150,-</td>
<td>175,-</td>
</tr>
<tr>
<td>Industry</td>
<td>750,-</td>
<td>850,-</td>
<td>950,-</td>
</tr>
<tr>
<td>SITC Members – Academia²</td>
<td>380,-</td>
<td>480,-</td>
<td>580,-</td>
</tr>
<tr>
<td>SITC Member – Junior Participant²</td>
<td>100,-</td>
<td>130,-</td>
<td>155,-</td>
</tr>
<tr>
<td>Foundations &amp; Charities</td>
<td>225,-</td>
<td>275,-</td>
<td>325,-</td>
</tr>
<tr>
<td>Press/Media Pass Registration³</td>
<td>No fee, but registration is mandatory</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Welcome Reception</td>
<td>No fee, but registration is mandatory</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conference Dinner for registered participants</td>
<td>75,-</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 The “Junior Participant” registration is available for Students under 30 years of age. Please provide a copy of a student ID at the moment of your registration.
2 Please provide the SITC Promotional Code during on site registration. Note: the reduced registration fee only applies if the code is provided – make sure to inquire with SITC prior to your on site registration.
3 A Press ID confirming your status must be provided at the moment of your registration.

IMPORTANT:
Reduced registration fees are only applicable, if they have been credited to the congress account before the respective deadlines. Registering before a deadline without performing an actual payment was not sufficient to benefit from the reduction. Please note that a different fee applies for onsite payments and registrations. If the fee is not transferred to the congress bank account before the respective deadline expires the fee will be changed to the next applicable fee automatically.

What is covered by the registration fee?
- Admission to all scientific sessions
- Abstract book and programme
- Welcome reception (no fee but registration mandatory)
- Coffee breaks & Lunches
- Admission to exhibition

Cancellations
Please note that only written cancellations addressed to ITOC5 c/o Vienna Medical Academy, Alser Straße 4, 1090 Vienna, Austria either per E-Mail: itoc@medacad.org or Fax: +43 1 405 13 83 918 can be accepted.

The following rules apply:
- before January 31, 2018: 50% refund
- after January 31, 2018: no refund

Replacements
Any replacement (i.e. change of delegate name) of a confirmed registration is subject to a 50 EUR charge per participant.
BADGES
For security reasons, badges will be checked upon access of the conference areas. Delegates are therefore requested to wear their badge at all times during the conference.

CATERING
Coffee breaks, lunches and a welcome reception have been scheduled. Exact times are listed in the programme overview.

CERTIFICATE OF ATTENDANCE
The 5th ImmunoTherapy of Cancer Conference is happy to introduce a digital CME acquisition system. You will be able to view and print a confirmation stating the according number of CME credits after finishing a survey requested by the UEMS. The link to the survey will be sent to all registered participants right after the conference. It is possible to claim a maximum of 15 CME points for attendance of scientific sessions at the ITOC5.

EXHIBITION
The exhibition is held in the "Atrium" of the Mercure Hotel MOA Berlin. Entrance is free for registered delegates but limited to healthcare professionals, press and exhibitors.

INSURANCE
By registering to the ITOC5 participants agree that neither the organising committee nor the congress office assume any liability whatsoever.
Participants are requested to make their own arrangements for health and travel insurance. The conference fee does not include insurance.

LANGUAGE & TRANSLATION
The official language of the conference is English. No simultaneous translation is provided.

LOST & FOUND
All enquiries should be directed to the registration desk situated on 1st Floor. The organizers accept no responsibility for loss due to theft or negligence.
NETWORKING EVENTS

Monday, March 19, 2018
Welcome Cocktail in the exhibition area of the venue Hotel Mercure MOA
No fee for registered participants, but registration is mandatory!

Tuesday, March 20, 2018
Conference Dinner
Altes Zollhaus
Carl-Herz-Ufer 30
10961 Berlin
www.altes-zollhaus-berlin.de
Time: 20.00 hrs
Bus departure from the venue Hotel Mercure MOA at 19.40 hrs
Contribution towards expenses: EUR 75,-

POLICIES
ITOC5 is accessible to all registered delegates. Children and members of the public are not permitted in the exhibition area or any room hosting an industry activity. In addition, the ITOC5 conference asks delegates and faculty to refrain from taking children and accompanying adults to any sessions or practical demonstrations. In the event that children are required to enter the conference centre, they should be supervised by an adult at all times and observe the restrictions that apply to limited access areas. In the event that a member of public is invited to participate in the ITOC conference scientific programme, they should be accompanied by a qualified healthcare professional or ITOC representative observing the ITOC restrictions where appropriate.
Advancing the Science and Application of Cancer Immunotherapy

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Established in 1984, SITC has more than 1,900 members representing 17 medical specialties in 38 countries, serving scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders. Through education programs that foster scientific exchange and collaboration, SITC aims to one day make the word “cure” a reality for cancer patients everywhere.

Among others, SITC resources include:

- **SITC 2018 Annual Meeting & Pre-Conference Programs**
  - November 7-11, 2018 in Washington DC

- **Journal for ImmunoTherapy of Cancer (JITC)**
  - SITC’s international, open access, peer-reviewed journal
  - Article processing charges are waived for SITC members through 2018 (a $2,500 value)

- **Upcoming Interim Workshops Focusing on Critical Next Steps in the Field**
  - May 14-15, 2018: Cancer Immune Responsiveness Workshop (San Francisco, Calif.)
  - May 16-17, 2018: Immuno-Oncology Biomarkers: State of the Art (San Francisco, Calif.)

- **SITC CONNECT Website (sitcancer.org)**
  - SITC’s hub for the latest news, research and community conversation related to cancer immunotherapy
  - **connectED**: SITC’s continuously growing selection of CE-certified cancer immunotherapy courses, presentation materials from past SITC events and more in this free online education portal

Learn more at sitcancer.org
transforming healthcare

FROM INSIGHT TO IMPACT

VISIT US AT BOOTH 12 AND DISCOVER:

• 3D Biology™ Technology for multi-analyte studies
• Digital Spatial Profiling Technology
• NanoString poster #P02.06: Digital spatial profiling platform allows for spatially-resolved, multiplexed measurement of solid tumor protein distribution and abundance in FFPE tissue sections.

LEARN MORE AT NANOSTRING.COM